Michael Makris/LinkedIn
Apr 17, 2026, 14:43
Michael Makris: Are Rebalancing Agents in Hemophilia Associated with Thrombosis?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about his recent article, published in the Journal of Thrombosis and Haemostasis։
”The PDF of my Forum article on the potential thrombogenicity of the ‘rebalancing’ agents is now available on the Journal of Thrombosis and Haemostasis website.”
Title: How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?
Author: Michael Makris
Other posts featuring Michael Makris on Hemostasis Today.
-
Jun 2, 2026, 11:04Melissa Glasner: The Safe and Effective Implementation of FXI/XIa Inhibitors Into Clinical Practice
-
Jun 2, 2026, 10:55Claudio Laudani: Not All ”Bi-Risk” PCI Patients Are Equal
-
Jun 2, 2026, 10:45Erin VanDyke: Creating a Multidisciplinary Forum Where VTE Remains a Visible Institutional Priority Is What Matters
-
Jun 2, 2026, 10:40Eseosa Ighodaro: A Free Online Stroke Education Series Is Now Live
-
Jun 2, 2026, 10:35Dawn Carter: What Does an Acute Stroke Diagnosis Tell Us, If It Never Shows Up in Hospital Data?
-
Jun 2, 2026, 10:19Wolfgang Miesbach: Attitudes Towards Gene Therapy for Severe Haemophilia in Germany
-
Jun 1, 2026, 18:51Francesco Giurazza: New Publication on Glubran-2 in Acute Bleeding Patients with Coagulopathies
-
Jun 1, 2026, 18:50Donald Arnold is the Recipient of the Roberts Award – ISTH
-
Jun 1, 2026, 18:49Amirreza Jabbaripour Sarmadian: My First Paper as Corresponding Author on Upper Extremity DVT Following COVID-19 Vaccination